English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60139
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorDavid-Cordonnier, Marie-Hélène-
dc.contributor.authorGajate, Consuelo-
dc.contributor.authorIglesia-Vicente, Janis de la-
dc.contributor.authorMollinedo, Faustino-
dc.date.accessioned2012-11-13T14:17:21Z-
dc.date.available2012-11-13T14:17:21Z-
dc.date.issued2005-
dc.identifierdoi: 10.1016/j.chembiol.2005.08.009-
dc.identifierissn: 1074-5521-
dc.identifier.citationChemistry and Biology 12(11): 1201-1210 (2005)-
dc.identifier.urihttp://hdl.handle.net/10261/60139-
dc.description.abstractWe have analyzed the DNA binding properties of the antitumor agent trabectedin (ET-743, Yondelis) and different analogs, namely, ET-745, lacking the C21-hydroxyl group, and ET-637, ET-594, ET-637-OBu, with modifications at the trabectedin C domain, versus their effects on cell cycle, apoptosis, and gene expression. ET-745 failed to bind DNA, highlighting the importance of the C21-hydroxyl group for DNA binding. Analogs ranked trabectedin ≫ ET-637 ≈ ET-594 > ET-637-OBu ≫ ET-745 for their DNA binding capacity; ET-637 and ET-594 display very different biological activities. Drugs were clustered in three major groups showing high (trabectedin, ET-637), intermediate (ET-637-OBu), and low (ET-594, ET-745) cytotoxic activity and similar transcriptional profiling responses. C21-hydroxyl-deficient analogs of the above-mentioned compounds showed a dramatic decrease in biological activity. Our data suggest that trabectedin interacts with an additional non-DNA target to raise an effective antitumor response, and that this interaction is favored through trabectedin-DNA complexes. ©2005 Elsevier Ltd All rights reserved.-
dc.description.sponsorshipThis work was supported by grants from Fondo de Investigación Sanitaria and European Commission (FIS04/0843, FIS02/1199), Fundación de Investigación Médica Mutua Madrileña (FMM), Fundación ‘‘la Caixa’’ (BM05-30-0), Junta de Castilla y León (CSI04A05) (to F.M.) C.G. was supported by the Ramón y Cajal Program from the Ministerio de Educación y Ciencia of Spain. -
dc.language.isoeng-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.titleDNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin-
dc.typeartículo-
dc.identifier.doi10.1016/j.chembiol.2005.08.009-
dc.date.updated2012-11-13T14:17:21Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.